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A suitable carrier for camptothecin to act as therapy against the hepatitis C virus is 
presented. The carrier relies on a hybrid dendritic-linear-dendritic block copolymer 
chemical structure that consists of a pluronic core functionalized at both ends with bis-
MPA dendrons. The amphiphilic pluronic core provides amphiphility and this allows 
the formation of micelles with a hydrophobic core and a hydrophilic shell. The 
dendrons admit the incorporation of multiple photoreactive groups that allow the 
covalent stabilization of the micelles by photocrosslinking. This process is clean and 
effective and affords crosslinked polymeric micelles (CLPM) susceptible of loading 
water soluble and non-water soluble molecules. Cell-uptake experiments using a newly 
designed fluorophore, derived from rhodamine B, demonstrate that the carrier favors the 
accumulation of its cargo within the cell. Furthermore, loaded with camptothecin, it 
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results efficient to fight against the hepatitis C virus while shows lower cytotoxicity 
than the free drug. 
1. Introduction
Among the various nanocarriers described and assayed as for drug delivery systems,[1] 
cross-linked polymeric micelles (CLPM), formed by amphiphilic block-copolymers, 
have shown successful for biomedical applications.[2] First, they can fulfil those general 
requirements for drug delivery systems: water solubility, low toxicity, to increase the 
stability of the drug inside the living organisms, to facilitate cellular uptake compared to 
free drug and to produce its controlled release at a specific location. Second, the 
amphiphilic nature of the constituent polymer results in a hydrophobic core and a 
hydrophilic shell that allow encapsulation of both types of drug. Third, these 
nanoparticles offer further stability under high dilution conditions, below the critical 
micellar concentration, compared to other polymeric micelles. Indeed, cross-linking 
avoids its disintegration in the bloodstream and the release of the drug before reaching 
the target cell. Particularly, fixation of the micelle structure by light-induced covalent 
cross-linking, mostly employing acrylate reactive groups,[3] represents a clean and 
effective procedure to prepare stable polymer micelles that can hold either water-soluble 
and non-water soluble molecules and transport them through the bloodstream.  
The features of nanocarriers, in general, and polymeric micelles, in particular, 
have been succesfully leveraged for anticancer therapies,[4] but are also attractive, and 
not extensively applied, for the development of systems to treat viral diseases.[5] In this 
respect, camptothecin (CPT), a poorly water soluble drug extracted in 1966 from the 
plant Camptotheca acuminate, which exhibits remarkable anticancer activity against 
different types of cancer,[6] has been recently described as a potent antiviral agent for 
Hepatitis C virus (HCV).[7] Indeed, a novel high throughput screening (HTS) strategy 
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for identifying potential antivirals led to the identification of this new potential 
pharmacological use of CPT.[8] However, CPT has some drawbacks that limit its 
applications, i.e. negligible water solubility[9] and chemical instability due to hydrolysis 
of its lactone ring under physiological conditions. To overcome this issue, different 
strategies have been adopted by researchers and several carriers for CPT have been 
described.[10] Nevertheless, none of them have been explored as for their potential for 
antiviral therapies.  
We herein present a new shell cross-linked polymeric micelle (CLPM) that 
shows high loading capacity for camptothecin while maintaining its antiviral activity 
and decreasing toxic effects. 
Figure 1. Chemical structure of the macromer F127-Ac-8. Schematic representation of 
micelle formation, shell-photocrosslinking and CPT loading.  
Based on our previous results about effective nanocarriers for antiviral drugs,[11]
we have selected a hybrid dendritic-linear-dendritic block copolymer (HDLDBC) 
structure[12] for the design of a suitable amphiphilic macromer to form polymeric 
micelles with a hydrophobic core and a hydrophilic cross-linkable shell (Figure 1). As 
for the lineal moiety, Pluronic F127 offers the ability to self-arrange in aqueous 
solutions forming micelles, which have proven to be excellent candidates for the 
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physical encapsulation of hydrophobic drugs,[13] with enhanced drug transport across 
cellular barriers.[14] This lineal block-copolymer is functionalized at both ends with 
dendritic blocks. The characteristic multivalency of dendritic blocks affords the 
possibility of multifunctionalization with photoreactive groups in the periphery so that 
to permit micelle shell-photocrosslinking. Dendritic blocks are based on 2,2-
bis(hydroxymethyl)propionic acid (bis-MPA) that provides a biocompatible and 
biodegradable scaffold.[15] In vitro cell-experiments have demonstrated that these 
nanoparticles permit the accumulation of their cargo within the cell using rhodamine B 
as a fluorescent probe. To further confirm cell internalization of the polymeric micelles, 
a new rhodamine B derivative with poor water solubility has been prepared to prevent 
fast release during the cell-internalization experiment. Finally, the potential of these 
nanoparticles as drug carriers for anti-HCV therapy has been studied with the poorly 
water-soluble drug CPT demonstrating that non-toxic CPT-loaded systems display 
similar anti-HCV-activity than free, and more toxic, CPT.  
2. Results and discussion
2.1. Synthesis and characterization of the amphiphilic HDLDBC 
macromer 
The macromer F127-Ac-8 was synthesized by divergent growing of 2nd generation bis-
MPA dendrons at both ends of commercial Pluronic F127 (Figure 2a). The synthetic 
pathway consists of five steps that provide each intermediate with high yields after easy 
purification processes when needed, i.e. F127-Bn-2, F127-Bn-4 and F127-Ac-8 were 
precipitated with cold ethyl ether from the reaction mixture and F127-OH-4 and F127-
OH-8 were used as-obtained without further purification.  
The terminal hydroxyl groups of Pluronic were esterified using the benzyl-
protected anhydride derived from 2,2-bis(hydroxymethyl) propionic acid. This acylating 
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agent was used in each step to grow the generation of the dendron following a 
debenzylation reaction to deprotect the terminal hydroxyl groups of the bis-MPA 
dendron, as described by Fréchet et al.[16] In the final stage, the terminal hydroxyl 
groups of both dendritic blocks were functionalized with acryloyl chloride in the 
presence of triethylamine. The final compound was fully characterized by 1H-NMR, 
13C-NMR, IR and MALDI-TOF. The complete conversion of the octahydroxy 
intermediate, F127-OH-8, into the octaacrylate derivative, F127-Ac-8, was assessed by 
1H-NMR, Figure 2b (see also ESI), with the appearance and correct integration of the 
signals corresponding to the protons of the acrylate group, labeled as q, q’ and r in 
Figure 2b.  
Figure 2. a) Synthesis of F127-Ac-8. Reagents and reaction conditions: (i) benzylidene-
2,2-bis(oxymethyl)propionic anhydride, DMAP, dichloromethane; (ii) Pd/C/H2, ethyl 
acetate; (iii) acryloyl chloride, TEA, dichloromethane. b) 1H-NMR spectra of F127-Ac-
8 in CDCl3, 300 MHz. c) CMC calculation: Intensities ratio I335/I332 versus log 










































Finally, the ability of the amphiphilic macromer F127-Ac-8 to self-aggregate in 
water so as to form micelles was determined by the pyrene method. This method is 
based on the displacement of the excitation maximum of pyrene from λmax=332 nm to 
λmax=335 nm when it is in a hydrophilic or a hydrophobic environment, respectively. 
Once formed the aggregates, pyrene locates in the hydrophobic core of the micelles and 
hence the intensity of the excitation maximum at 335 nm (I335) increases in detriment of 
the band at 332 nm (I332). The representation of the I335/I332 intensity ratio versus 
logarithm of the concentration of pyrene leads to a curve, where CMC is determined by 
calculating the intersection of the two straight lines. 
In order to obtain the corresponding curve, F127-Ac-8 solutions were prepared 
at 0.001, 0.01, 0.1, 0.5, 1, 3, 5 and 10 mg/mL. Then, a similar amount of pyrene was 
added in each sample, with a final pyrene concentration of 6x10 -8 M. The excitation 
spectrum of the samples was measured in the range of 300 to 350 nm with λemission = 390 
nm.  A critical micellar concentration of 0.11 mg/mL was determined for F127-Ac-8 
(Figure 2c). 
2.2. Preparation and morphological characterization of CLPMs 
Upon formation of the micelles of F127-Ac-8, these could be stabilized by intramicellar 
photocrosslinking providing stable polymeric nanoparticles.[3] The photoinduced 
polymerization was carried out using 7.7 mg/mL aqueous solutions of the macromer 
containing 1 mg/mL of Irgacure 2959 as a biocompatible photoinitiator. The solution 
was irradiated with UV light, λ= 365 nm, at 25 ⁰C for 10 minutes.[3b,17] Subsequent 
dialysis at 4 ⁰C for 72 hours, and filtration through 0.2 µm cellulose acetate filters 
yielded a solution of nanoparticles at a final concentration of 1.9±0.1 mg/mL, which 
was used for further studies. 
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The so-prepared CLPMs were observed by TEM and SEM, and showed a spherical 
morphology (Figure 3).  
Figure 3. a) TEM image and b) SEM image for F127-Ac-8 CLPMs. 
The size of the photopolymerized particles was studied by DLS. A mean diameter of 
127±9 nm (polydispersity: 0.56±0.07) was determined at 25 ºC, whereas a smaller mean 
diameter of 102±1 nm (polydispersity: 0.36±0.02) was determined at 37 ⁰C. The 
observed size variation with temperature confirmed that the nanoparticles display 
thermosensitive behavior, provided by Pluronic-F127. This temperature-dependent 
feature should also help to validate these CLPMs as suitable candidates for responsive 
drug carriers.[18]  
2.3. Encapsulation of fluorescent probes and cell-uptake studies 
For cell-uptake studies of the F127-Ac-8 CLPMs, water-soluble rhodamine B [Rho-B] 
(Figure 4a) was first used as a fluorescent probe. The encapsulation of Rho-B into the 
CLPM was carried out by the solvent evaporation method, using ethanol as the volatile 
solvent. Rho-B was dissolved in ethanol at 0.15 mg/mL concentration. A 0.15 mg/mL 
solution of Rho-B was added over CLPMs F127-Ac-8 solution at a feed ratio of 0.15 
mg of Rho-B /mg of CLPM. The mixture was incubated at room temperature for 24 
hours. Ethanol was evaporated with orbital agitation. After dialysis for 24 h, the amount 
of encapsulated Rho-B was calculated indirectly as the difference between the initial 
quantity of Rho-B added and the amount of Rho-B present in the dialysis solution, 
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determined by fluorescence. Accordingly, an encapsulation efficiency (EE) of 50.6% 
was calculated.[2g]  
Cell-uptake experiments were performed on HeLa cells. The cells were 
incubated with a solution of 0.6 mg/mL Rho-B loaded CLPMs for 4 h at 37 ºC.  For the 
co-localization of Rho-B labeled CLPMs using confocal microscopy, staining of actin 
was performed with Alexa Fluor 488 Phalloidin. Confocal images (Figure 4b and 4c) 
suggest that F127-Ac-8 CLPMs allow the accumulation of Rho-B within the cell. 
Nevertheless, since Rho-B is highly soluble in water, it is still possible that, in the high 
dilution conditions of culture media, Rho-B releases from the nanoparticles and enters 
into the cells by simple diffusion induced by a concentration gradient.  
Figure 4. a) Chemical structure of Rhodamine B. b) and c) confocal microscopy images 
for HeLa cells incubated with Rho-B-loaded nanoparticles. d) Chemical structure of the 
derivative of rhodamine B incorporating a hydrophobic block, Rho-B-2C18. e) and f) 
confocal microscopy images for HeLa cells incubated with Rho-B-2C18 loaded 
nanoparticles. b) and e) images correspond to cellular nuclei stained with DAPI in blue 
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and Rho-B or Rho-B-2C18 appear in pink. c) and f) images exhibit also the green 
fluorescence due to cytoskeleton stained with Alexa Fluor 488 Phalloidin. 
In order to prevent fast release of the fluorescent probe from the CLPMs during 
the experiment time, a newly designed Rho-B fluorescent probe [Rho-B-2C18], which 
contains a hydrophobic block that confers it negligible solubility in water, was designed 
(Figure 4d). Rho-B-2C18 was synthesized by copper-catalyzed 1,3-dipolar azide-alkyne 
cycloaddition between an azide derivative of rhodamine-B and a first generation bis-
MPA dendron functionalized by esterification of the hydroxyl groups with stearic acid. 
The encapsulation of Rho-B-2C18 was carried out using the same methodology 
described for Rho-B. The analysis of the dialysis solution revealed the absence of Rho-
B-2C18, yielding an EE of 100%, likely due to the enhanced interactions between its 
hydrophobic block and the hydrophobic regions in the CLPM. Cell-uptake experiments 
were performed under the same conditions as for Rho-B loaded CLPMs. Similarly, 
confocal images showed accumulation of fluorescence within the cell after 4 h 
incubation at 37 ºC (Figure 4e and 4f), thus confirming internalization of nanoparticles 
into the cells.  
2.4. Camptothecin encapsulation 
In order to explore the possibility of these CLPMs to act as nanocarriers for anti HCV 
drugs, we undertook cytotoxicity and anti-HCV activity experiments based on 
encapsulated CPT. 
Due to the insolubility of CPT in volatile water-soluble solvents, the evaporation 
method could not be employed for the encapsulation. Instead, a solution (0.15 mg/mL) 
of CPT in DMSO was added into the F127-Ac-8 CLPMs solution (1.9±0.1 mg/mL) 
until a ratio of 0.15 mg of CPT per mg of CLPM was reached. The mixture was 
incubated at room temperature for 24 hours. DMSO was eliminated by dialysis 
(Spectra/Por® MWCO 2000, Spectrum), causing non-encapsulated CPT precipitation. 
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The elimination of non-encapsulated CPT was carried out by filtration with 0.45 µm 
Teflon filters. Encapsulated CPT quantification was made directly by taking 5 µL of 
filtered solution, which was previously lyophilized and re-dissolved in a known volume 
of DMSO. CPT was quantified by fluorescence emission spectrum (λmax= 436 nm in 
DMSO with λexc=368 nm) by using a calibration curve in the concentration range 11.2-
39.2 µg/mL in DMSO. The final concentrations of the solution were 0.42 mg/mL of 
CLPMs and 18.8 µg/mL of CPT. This result corresponds to an Encapsulation Efficiency 
(EE %) of 32.7 %,[2g] a drug loading content of 4.5 % and a loading capacity of 44.6 µg 
of CPT/mg of F127-Ac-8 CLPMs. 
The encapsulation process of CPT within the F127-Ac-8 CLPMs was studied by 
isothermal titration calorimetry, ITC. Experiments were performed at 25°C in aqueous 
media with 3% of DMSO to increase solubility. 100 µM CPT solution in the 
calorimetric cell was titrated with F127-Ac-8 polymer 30 µM solution. Control 
experiments were performed under the same experimental conditions. The heat evolved 
after each ligand injection was obtained from the integral of the calorimetric signal 
(Figure 5).  
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Figure 5. Camptothecin/F127-Ac-8 interaction by isothermal titration calorimetry. 
Calorimetric titrations were performed by programming sequential injections of 
Camptothecin solution (0.035 mg/mL) into F127-Ac-8 solution (0.42 mg/mL) in the 
calorimetric cell. Upper plot shows the thermogram (thermal power to maintain a zero 
temperature difference between the reference and sample cells as a function of time) 
and lower plot shows the binding isotherm (normalized heat per injection as a function 
of molar ratio). From a simple analysis considering n identical and independent binding 





) and the interaction enthalpy (H = 6.8 kcal/mol) could be estimated.
The association constant (Ka) and the enthalpy change (ΔH) were obtained 
through non-linear regression of experimental data to a model considering one class of 
ligand binding sites. The results reflected that CPT encapsulation is energetically 
favoured with an association constant Ka = 1.5107 M-1, corresponding to a moderate-to-
high Gibbs energy of interaction (ΔG = -9.8 kcal/mol) dominated by the entropic 







































contribution (-TΔS = -16.6 kcal/mol), with an unfavourable interaction enthalpy (ΔH = 
6.8 kcal/mol), as expected for a predominantly hydrophobic interaction between the 
drug and the hydrophobic region of the CLPMs. Thus, the F127-Ac-8 CLPM-drug 
calorimetric titrations show that CPT interacts specifically with F127-Ac-8.  
2.5. In-vitro anti-HCV studies 
Once confirmed the cell internalization of the CLPMs to deliver a cargo and the 
possibility of loading CPT into these nanoparticles, the next step was to study the 
efficacy of the CPT-carrier system as for the inhibition of HCV replicon.  
Nevertheless, prior to this study and in order to check the cytotoxicity of the system, we 
performed cell viability studies on HeLa cells for a range of concentrations of free CPT 
and F127-Ac-8/CPT CLPMs, close to those used in subsequent antiviral experiments. 
Figure 6 represents the viability of HeLa cells upon incubation for 3 days. The results 
show that the cytotoxic effect of free CPT is reduced when CPT is encapsulated into 
F127-Ac-8 CLPMs. The CC50 of encapsulated CPT is 0.32 ± 0.03 µM, compared to 
0.26 ± 0.03 for free CPT. 
Figure 6.  Cell viability for F127-Ac-8 CLPMs on HeLa cells: free F127-Ac-8 CLPMs 
(black), F127-Ac-8/CPT CLPMs (green) and free CPT (red). Continuous lines are non-
linear fittings to the dose-response equation. 

























For inhibition of HCV replicon assays, Huh5-2 cells were incubated with a 
control of free CPT and F127-Ac-8/CPT CLPMs. Cell viability data for Huh 5-2 and % 
of viral load reduction are represented in the same double axis graph (Figure 7). 
Figure 7.  Inhibition of HCV replicon in Huh5-2 cells. Evaluation of potency and 
cytotoxicity in Huh5-2 cells. Cell survival (bars) and HCV replicon replication rate 
(lines and symbol) were assessed in cell culture at increasing compound concentration 
to determine CC50 and EC50: free CPT (grey bars and green line) and F127-Ac-8/CPT 
CLPMs (red bars and violet line). *UTC: untreated controls. 
For both cell types (HeLa and Huh 5-2) a slight decrease in toxicity of F127-Ac-
8/CPT CLPMs in comparison to free CPT was observed (Figure 6 and 7). Also, the anti-
HCV activity was not the result of a cytostatic or cytotoxic effect, since cell viability 
remained near 100% at the EC50 values. Non-loaded F127-Ac-8 CLPMs, at the same 
conditions, did not promote any effect in the virus replication cycle or viability (data not 
shown). The behaviour of free CPT and F127-Ac-8/CPT CLPMs is very similar and 
their EC50 values, i.e. 0.013 ± 0.002 μM and 0.032 ± 0.01 μM, respectively, are very 
close in nanomolar order. Interestingly, cell viability is always slightly higher for 













































cell viability can be observed at 1 µM concentration, when the viral load has been 
nearly totally reduced. This would be specially interesting if CPT is intended as an 
antiviral agent, instead of an antitumor drug (its approved pharmaceutical application 
based on its high cytotoxicity in mammalian cells).[19]
3. Conclusion
In conclusion, these results open new possibilities for the molecular design of cross-
linked polymeric micelles for antiviral therapy applications. Particularly, the macromer 
F127-Ac-8, with a hybrid dendritic-lineal-dendritic block copolymer structure provides 
a molecular design that takes advantage of the amphiphilic nature of Pluronic and the 
multivalency provided by the dendritic blocks to achieve micelle stabilization by 
photocrosslinking and high loading capacity. The cytotoxicity of the drug is reduced 
when encapsulated, while the same efficacy of the free drug against the hepatitis-C virus 
is maintained. Interestingly, the multivalency of this dendritic block molecule can be 
exploited towards the multiconjugation of the polymeric micelles with active groups 
such as targeting moieties, offering future prospects for this sort of amphiphilic reactive 
compounds.  
4. Experimental Section
4.1. Materials  
Pluronic F127® (Average Mw= 12600), acryloyl chloride, 4-dimethyl-aminopyridine 
(DMAP), 2,2-bis(hydroxymethyl)propionic acid (bis-MPA), acryloyl chloride, 
triethylamine (TEA), 1,3-dicyclohexylcarbodiimide (DCC), benzaldehyde dimethyl 
acetal, p-toluensulfonic acid monohydrate, 2-hydroxy-1-(4-(hydroxyethoxy) phenyl)-2-
methyl-1-propanone (Irgacure 2959, I2959), rhodamine B, CuSO4.5H2O, (L)-ascorbate 
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and camptothecin were obtained from Sigma-Aldrich. Pluronic F127® was dried during 
3 hours at 100 ⁰C under vacuum prior to use. All solvents were purchased from Sigma-
Aldrich.  4-(dimethylamino) pyridinium 4-toluenesulfonate (DPTS), 6-azido-hexan-1-
ol, 2-(but-3-ynoyl)-2-methylpropane-1,3-diyl distearate (HCC-2C18)[11] and 
tris(benzyltriazolylmethyl)amine[20] (TBTA) were synthesized according to previous 
reported procedures.  
DMEM (Dulbecco´s Modified Eagle´s Medium, 4.5g/l glucose), DMEM/F-12 
(Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12), DPBS (Dulbecco´s 
Phosphate Buffered Saline), L-glutamine, 1X non-essential amino acids, Geneticin 
(G418) and Alamar Blue reagent were purchased from Gibco. Penicillin/Streptomycin 
(5000U/ml), Amphotericin B (250µg/ml) and Trypsin (Trypsin-Versene 10X) were 
obtained from Lonza. Alexa-Fluor488-labeled-Phalloidin and DAPI (4',6-Diamidino-2-
Phenylindole, Dilactate) were purchased from Invitrogen. Paraformaldehyde (PFA) and 
bovine serum albumin (BSA) were supplied by Sigma−Aldrich. Mowiol and Saponin 
from Merck Millipore. Fetal bovine serum (PAN-Biotech GmbH, Germany). Bright-
GloTM Luciferase Assay System (Promega Corporation), CellTiter 96 AQueous One 
Solution Cell Proliferation Assay (Promega Corporation).  
4.2. Synthesis and characterization of F127-Ac-8 
F127-Bn-2. Pluronic F127® (10.0 g, 0.79 mmol) was dissolved in dry dichloromethane 
(20 mL). DMAP (0.12 g, 0.95 mmol) and benzylidene-2,2-bis(oxymethyl)propionic 
anhydride (2.0 g, 4.76 mmol) were added. The mixture was stirred at room temperature 
overnight. The excess of anhydride was quenched by adding methanol (6 mL). The 
mixture was stirred overnight and the crude was precipitated in cold diethyl ether (1 L). 
The product was isolated as a white powder after filtration. Yield: 95 %. 1H-NMR (400 
MHz, CDCl3, δ): 1.04 (s, 6H, -CH3), 1.13 (m, 201H, -CH3), 3.37-3.82 (m, ~1100H, -O-
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CH2-CH2-O-), 4.35 (m, 4H, -CH2-CH2-OC(O)-), 4.66 (d, J=11.6 Hz, 4H, -CH2-OC(O)-
), 5.44 (s, 2H, -CH-Ph), 7.32 (m, 6H, Ar H), 7.42 (m, 4H, Ar H); 13C-NMR (100 MHz, 
CDCl3, δ): 17.3, 17.4, 17.9, 42.4, 64.2, 68.5, 68.6, 69.1, 70.5, 72.9, 73.3, 75.1, 75.3, 
75.5, 101.7, 126.2, 128.2, 128.9, 137.9, 173.9; IR (molten polymer over NaCl): ν = 
2883 (C-H st), 1737 (C=O st), 1114 (C_O_C st) cm-1; MALDI+ maximum m/z 5050.2 
and 13297.2. Anal. calcd. for C621H1220O272: C 57.29, H 9.38; found: C 56.68, H 9.55. 
F127-OH-4. F127-Bn-2 (9.5 g, 0.73 mmol) was dissolved in ethyl acetate (200 mL). 
Then, Pd/C (10 % by weight) was added. After three vacuum-argon cycles, the reaction 
mixture was stirred at room temperature in hydrogen atmosphere overnight. The Pd/C 
was filtered off with Celite® and the filtrate was evaporated to give a white solid. Yield: 
Quant. 1H NMR (300 MHz, CDCl3, δ): 1.11 (s, 6H, -CH3), 1.13 (m, 201H, -CH3), 3.37-
3.82 (m, ~1100H, O-CH2-CH2-O-), 4.34 (m, 4H, G, -CH2-CH2-OC(O)-); 
13C NMR (75 
MHz, CDCl3, δ): 17.1, 17.3- 17.4, 49.5, 63.2, 67.3, 68.7, 70.5, 72.9, 73.3, 75.1, 75.3, 
75.5, 175.6; IR (molten polymer over NaCl): ν  = 3482 (OH), 2884 (C-H st), 1728 
(C=O), 1112 (C_O_C) cm-1; MALDI+: maximum m/z 5213.9 and 13780.1; Anal. calcd. 
for C607H1212O272: C 56.42, H 9.44; found: C 56.04, H 9.98. 
F127-Bn-4. F127-OH-4 (4 g, 0.31 mmol) was dissolved in dry dichloromethane (15 
mL). Benzylidene-2,2-bis(oxymethyl)propionic anhydride (2.13 g, 4.99 mmol) and 
DMAP (122 mg, 1 mmol) were added after dissolution. The reaction was stirred at 
room temperature for 72 hours. The excess of anhydride was quenched by adding 
methanol (6 mL). The mixture was stirred for 7 hours and the crude was precipitated in 
cold diethyl ether (1 L). The product was isolated after filtration as white solid. Yield: 
95 %. 1H NMR (300 MHz, CDCl3, δ): 0.93 (s, 12H, -CH3), 1.13 (m, 201H, -CH3), 1.24 
(s, 6H, -CH3), 3.37-3.82 (m, ~1100H, -O-CH2-CH2-O- and -CH2-OC(O)-), 4.11 (m, 4H, 
-CH2-CH2-OC(O)-), 4.37 (s, 8H, -CH2-OC(O)-), 4.56 (d, J=11.5 Hz, 8H, -CH2-OC(O)-
17 
), 5.40 (s, 4H, -CH-Ph), 7.28 (m, 12H, Ar H), 7.38 (m, 8H, Ar H); 13C-NMR (75 MHz, 
CDCl3, δ): 17.4, 17.6, 17.7, 42.5, 46.7, 64.1, 65.4, 68.5, 70.5, 72.9- 73.3, 75.1- 75.3- 
75.5, 101.6, 126.1, 128.0, 128.8, 137.7, 173.1; IR (molten polymer over NaCl): ν = 
2883 (C-H st), 1741 (C=O), 1113 cm-1 (C_O_C). MALDI+: maximum m/z 5615.9 and 
13844.4. Anal. calcd for C655H1260O284: C 57.59, H 9.23; found: C 56.89, H, 9.74. 
F127-OH-8. F127-Bn-4 (2.8 g, 0.21 mmol) was dissolved in ethyl acetate (100 mL). 
Then Pd/C (10 % by weight) was added. After three vacuum-argon cycles, the reaction 
mixture was stirred at room temperature in hydrogen atmosphere overnight. The Pd/C 
was filtered off with Celite® and the filtrate was evaporated to give the product as a 
white solid. Yield: Quant %. 1H-NMR (400 MHz, CDCl3, δ): 1.05 (s, 12H, -CH3), 1.13 
(m, 201H, -CH3), 1.28 (s, 6H, -CH3), 3.37-3.79 (m, ~1100H, O-CH2-CH2-O-), 4.26-4.38 
(q, 8H, Δѵ´=35 Hz, J´= 11.2 Hz, -CH2-OC(O)-), 4.26 (m, 4H, -CH2-CH2-OC(O)-); 13C-
RMN (100 MHz, CDCl3, δ): 17.1, 17.3- 17.4, 17.9, 46.4, 49.7, 64.3, 64.9, 67.3-67.4, 
68.5-68.8, 70.5, 72.9- 73.3, 75.1- 75.3- 75.5, 172.9, 174.9; IR (molten polymer over 
NaCl): ν = 3457 (OH), 2884 (C-H st), 1733 (C=O), 1113 cm-1 (C_O_C); MALDI+: 
maximum m/z 5286.1 and 13693.8; Anal. calcd for C627H1244O284: C 56.59, H 9.36, 
found: C 56.17, H 9.98. 
F127-Ac-8. F127-OH-8 (1.5 g, 0.11 mmol) was dissolved in of dry dichloromethane 
(20 mL). Then, triethylamine (0.55 ml, 3.98 mmol) and p-methoxyphenol (200 mg, 
polymerization inhibitor) were added. The reaction was cooled for 10 minutes in an ice 
bath and acryloyl chloride (0.29 ml, 3.61 mmol) was added dropwise under argon 
atmosphere. The mixture was stirred at room temperature for 14 hours in the dark. The 
solution was passed through a neutral alumina column and the filtrate was dried with 
Na2CO3 during 2 hours. The product was purified by precipitation in cold diethyl ether 
(250 mL). The product was obtained after filtration as a white solid. Yield: 80 %. 1H 
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NMR (300 MHz, CDCl3, δ): 1.13 (m, 201H, -CH3), 1.23 (s, 6H, -CH3), 1.27 (s, 12H, -
CH3), 3.37-3.87 (m, ~1100H, -O-CH2-CH2-O-), 4.23-4.30 (m, 28H, -CH2-OC(O)- and -
CH2-CH2-OC(O)-),  5.85 (dd, Jcis=10.4 Hz, Jgem=1.3 Hz, 4H, H2C=CH-), 6.10 (dd, 
Jtrans=17.3 Hz, Jcis=10.4 Hz, 4H, H2C=CH-), 6.39 (dd, Jtrans=17.3 Hz, Jgem=1.3 Hz, 4H, 
H2C=CH-); 
13C NMR (125 MHz, CDCl3, δ): 17.3- 17.4, 17.7, 45.8, 46.5, 64.9, 65.3-
65.6, 68.5-68.7, 70.5, 72.9- 73.3, 75.1- 75.3- 75.5, 127.7, 131.5, 165.4, 171.9-172.0; IR 
(molten polymer over NaCl): ν = 2867 (C-H st), 1733 (C=O), 1109 cm-1 (C_O_C). 
MALDI+: maximum m/z 5761.4 y 14176.6; Anal. calcd for C651H1260O292: C 56.90, H 
9.18; found: C 56.48, H, 9.66.  
4.3. Synthesis and characterization of Rho-B-2C18 
Rho-B-N3. Rhodamine B (1.00 g, 2.09 mmol) was dissolved in dry dichloromethane 
(70 mL). 6-azido-hexan-1-ol (602 mg, 4.18 mmol) and DPTS (492 mg, 1.67 mmol) 
were added after the dissolution. The reaction was stirred at 45 ºC under Argon 
atmosphere. DCC (861 mg, 4.18 mmol) was dissolved in dry dichloromethane (10 mL) 
and was added dropwise to the reaction mixture. It was stirred at 45ºC under Argon 
atmosphere overnight, protected from the light. A white precipitate appeared, which was 
filtered off. Dichloromethane (20 mL) were added to the filtrate. It was washed once 
with 100 mL of HCl 1.0 M and twice with 100 mL of brine. The organic phase was 
dried over anhydrous MgSO4 and the solvent was evaporated under reduced pressure. 
The crude product was purified on silica gel (DCM:MeOH = ramp from 10:0 to 9:1) to 
give a purple solid. Yield: 74 %. 1H NMR (400 MHz, CDCl3): δ (ppm): 1.32 (t, J = 8 
Hz, 12H, N-CH2-CH3), 1.49 (m, 4H, -CH2-CH2-CH2-CH2-), 1.65 (tt, J = 12 Hz, 2H, N3-
CH2-CH2-), 1.87 (tt, J = 12 Hz, 2H, -CH2-CH2-O-), 3.23 (t, J = 4 Hz, 2H, N3-CH2-), 
3.63 (q, J = 8 Hz, 8H, -N-CH2-CH3), 4.02 (t, J = 8 Hz, 2H, -CH2-O), 6.82 (d, J = 4 Hz, 
2H, Ar H), 6.89 (dd, J = 8 Hz, J < 4Hz, 2H, Ar H), 7.07 (d, J = 8Hz, 2H, Ar H), 7.30 
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(dd, J = 8 Hz, J < 4Hz, 1H, Ar H), 7.75 (td, J = 8 Hz, J = 4 Hz, 1H, Ar H), 7.82 (td, J = 8 
Hz, J = 4 Hz, 1H, Ar H), 8.29 (dd, J = 8 Hz, J < 4Hz, 1H, Ar H); 13C NMR (75 MHz, 
CDCl3): δ (ppm) 12.6, 25.4, 26.3, 28.2, 28.6, 46.2, 51.3, 65.5, 96.5, 113.6, 114.3, 126.3, 
128.5, 130.0-130.3-130.4, 131.3, 133.1, 133.5, 155.5, 157.7, 165.1. Note: the counter-
ions are a mixture of C7H7SO3
- and Cl-; C7H7SO3
- was observed in 1H NMR (2.26 (s, 
2.4H), 7.07 (d, J = 8 Hz, 1.6H), 7.9 (d, J = 8 Hz, 1.6H) and 13C NMR (21.3, 127.0, 
129.7, 139.4, 158.9). IR (ATR mode): ν = 2928 and 2852 (C-H st), 2095 (N3), 1715 
(C=O), 1645-1585 cm -1 (C-Car). MS (ESI
+): m/z: [M+] calcd for C34H42N5O3 568,32; 
found, 568,39. Anal. calcd for C34H42N5O3
+, Cl- / C7H7SO3
-: C 66.8, H 6.7, N 9.9, S 3.5; 
found: C 66.3, H 7.0, N 10.0, S 3.7. 
Rho-B-2C18. Rho-B-N3 (200 mg, 0.33 mmol) and HC≡C-2C18 (280 mg, 0.40 mmol) 
were dissolved in dry dimethylformamide (7 mL) and the mixture was stirred at 45ºC. 3 
cycles of vacuum-argon were made to remove O2. CuSO4.5H2O (9.8 mg, 0.03 mmol), 
(L)-ascorbate (13.1 mg, 0.07 mmol) and TBTA (17.6 mg, 0.003 mmol) were dissolved 
in dry dimethylformamide (3 mL) and the mixture was stirred at 45ºC. 3 cycles of 
vacuum-argon were made to remove O2. After 15 min, the Cu(I) solution was added to 
the first one through a canula. 3 cycles of vacuum-argon were made to remove O2. The 
reaction mixture was stirred at 45ºC for 24 hours protected from the light. A mixture of 
brine and water (1:1) (100 mL) were added to the reaction mixture. The product was 
extracted 3 times with dichloromethane (3 x 70 mL). The organic phases were dried 
over anhydrous MgSO4 and the solvent was evaporated under reduced pressure. The 
crude product was purified on silica gel (DCM:MeOH = ramp from 100:0 to 92:8) to 
give a purple solid. Yield: 46 %. 1H NMR (400 MHz, CDCl3, δ): 0.87 (t, J = 6.4 Hz, 6H, 
-(CH2)17-CH3), 1.24 (m, 71H, -CH2-CH2-CH2-CH2, -(CH2)14-, -CH3), 1.33 (t, J = 8 Hz, 
12H, -N-CH2-CH3), 1.44 (m, 2H, -CH2-CH2-O-), 1.56 (m, 4H, -(CH2)14-CH2-CH2-
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C(O)O-), 2.25 (t, J = 7.2Hz, 4H, -(CH2)14-CH2-CH2-C(O)O-), 3.63 (q, J = 6,8 Hz, 8H, -
N-CH2-CH3), 4.01 (t, J = 6 Hz, 2H, -CH2-CH2-O-), 4.21 (AB, 4H, -CH2-O-), 4.43 (t, J = 
5.6 Hz, 2H, -C2H1N3-CH2-CH2-), 5.25 (s, 2H, -O-CH2-C2H1N3-), 6.95 (m, 4H, Ar H), 
7.10 (d, J = 8Hz, 2H, Ar H), 7.30 (d, J = 8 Hz, 1H, Ar H), 7.35 (s, 1H, -C2H1N3-), 7.77 
(m, 2H, J, Ar H), 8.30 (d, J = 8 Hz, 1H, Ar H), note: The signal of the protons -C2H1N3-
CH2-CH2- (near 1.90 ppm) is overlapped with water signal and cannot be observed; 
13C 
NMR (75 MHz, CDCl3, δ): 12.6, 14.1, 17.8, 22.6-24.9, 25.2, 26.2, 28.1, 28.0, 29.0-29.2-
29.3-29.4-29.6-30.0-31.9-34.0, 46.3, 50.7, 64.9, 65.5, 95.6, 113.6, 114.3, 119.1, 124.3, 
126.3, 128.5, 130.0-130.3-130.4, 131.3, 133.0, 133.4, 155.5, 157.7, 165.1, 172.6, 173.2; 
IR (ATR mode): ν = 2916 - 2851 (C-H st), 1740 - 1715 (C=O), 1649-1587 cm-1 (C-Car), 
note: A peak corresponding to water is observed at 3406 cm-1. MALDI+: m/z (%) 
1273.1 (100) [C78H122N5O8, H2O]
+. 
4.4. Chemical characterization techniques 
The 1H NMR and 13C NMR spectra were recorded from their corresponding solutions in 
CDCl3, operating at 300/75 MHz (Bruker AMX300) or 400/100 MHz (Bruker AV-400). 
IR spectra (Thermo Nicolet Avatar 360 FT-IR spectrometer) of F127-Bn-2, F127-OH-4, 
F127-Bn-4, F127-OH-8 and F127-Ac-8 were registered from molten polymer over a 
NaCl tablet whereas IR spectra (JACSO FT/IR-4100) of Rh-B-N3 and Rh-B-2C18 were 
registered in ATR mode. Mass spectrometry was performed using a ESI Bruker Esquire 
3000 plus spectrometer for Rh-B-N3 and with a MALDI/TOF-MS Bruker Microflex 
system for the rest of the products. Elemental analysis was obtained in a microanalizer 
Perkin Elmer CHN 2400. GPC was performed in a Waters 2695 apparatus equipped to a 
light scattering detector Waters 2424. 
4.5. Preparation of CLPMs 
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A 10% (w/v) solution of F127-Ac-8 containing 0.1 % of photoinitiator I2959 was 
prepared in distilled water and kept overnight at 4ºC for complete dissolution of the 
polymer. The final solution was filtered through a 0.2 µm acetate cellulose filter to 
remove possible particles in suspension. By dilution with filtered distilled water 
containing 0.1 % of photoinitiator, 0.77% (w/v) solutions were prepared, which were 
used for photopolymerization. 0.77% precursor solutions were equilibrated for 1 hour at 
room temperature. 5 mL of 0.77% precursor solutions were light cured in a 6 cm 
diameter cylindrical glass container, using UV light (λ= 365 nm, 25 ºC, 10 minutes) 
with a distance of 8 cm between the lamp and the sample. The photopolymerized 
solution was dialyzed at 4 ºC for 72 hours, using a cellulose acetate membrane (Spectra 
/ Por ® Biotech 300,000 MWCO (Spectrum)), with daily water changes. In order to 
remove larger aggregates, dialyzed samples were filtered with 0.2 µm cellulose acetate 
filters. To calculate the final concentration, known volumes of this dialyzed and filtered 
solution of CLPMs were dried by lyophilization in order to weigh the residue. A mean 
concentration of 1.9±0.1 mg/mL was determined from three freeze-drying experiments. 
4.6. CLPM characterization  
Dynamic light Scattering (DLS). The size of the CLPMs was measured by DLS at two, 
25 ºC and 37 ºC, using a Malvern Instrument Nano ZS that uses a He-Ne laser, 633 nm 
and a detection angle of 173o. 
Transmission Electronic Microscopy (TEM) and Scanning Electronic Microscopy 
(SEM). The morphology of the CLMPs was observed by TEM (TECNAI G20, 200kV) 
and SEM (Inspect F50). TEM samples were prepared by adding a drop of CLMPs 
solution in a TEM grid (HOLLEY carbon film 300 mesh Cu, Agar, Scientific). Water 
from the sample was removed by capillarity with a filter paper. The sample was dried 
overnight in the darkness. SEM samples were prepared by adding a drop of CLMPs 
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solution in a 12 mm glass coverslip. Sample was allowed to dry overnight in the 
darkness and gold sputtered before SEM observation. 
4.7. Rho-B and Rho-B-2C18 encapsulation and loading content determination 
Rho-B or Rho-B-2C18 was dissolved in ethanol at 0.15 mg/mL concentration. Rho-B or 
Rho-B-2C18 solution was added over CLPMs F127-Ac-8 solution at a feed ratio of 0.15 
mg of Rho-B or Rho-B-2C18/mg of CLPM. The mixture was incubated at room 
temperature for 24 hours. Ethanol was evaporated with orbital agitation. 
Aqueous solution containing Rho-B loaded CLPMs were dialyzed (Slide-A - Lyzes ® 
dialysis Cassette G2 2,000 MWCO, Thermo Scientific) with distilled water for 24 hours 
to remove the non-encapsulated Rho-B. Non-encapsulated Rho-B quantification was 
carried out by fluorescence (λmax = 576 nm in water) by using a calibration curve in the 
concentration range 2.5-38 µg/mL in water. The amount of encapsulated Rho-B was 
calculated indirectly as the difference between the initial feed of Rho-B added and the 
amount of Rho-B present in the dialyzed solution.  
For Rho-B-2C18 no further purification was necessary after ethanol evaporation, due to 
no precipitation of Rho-B-2C18, indicating a complete encapsulation for Rho-B-2C18. 
4.8. Camptothecin encapsulation and loading content determination 
CPT was dissolved in DMSO at 0.15 mg/mL. The CPT solution was added over a F127-
Ac-8 CLPMs solution (1.9 mg/mL) at a feed ratio of 0.15 mg of CPT/mg of CLPM. The 
mixture was incubated at room temperature for 24 hours. DMSO was eliminated by 
dialysis (Spectra/Por® MWCO 2000, Spectrum), causing non-encapsulated 
camptothecin precipitation. Elimination of non-encapsulated CPT was carried out by 
filtration with 0.45 µm teflon filters. Encapsulated CPT quantification was made 
directly by taking 5 µL of filtered solution, which was previously lyophilized and 
redissolved in a known volume of DMSO. CPT was quantified by fluorescence 
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emission spectrum (λmax= 436 nm in DMSO with λexc=368 nm) by using a calibration 
curve in the concentration range 11.2-39.2 µg/mL in DMSO.  
4.9.  In-vitro cellular uptake 
HeLa cells were seeded at a density of 40·103 cells per well in 24 multiwell culture 
plates over sterile glass covers. Cells were grown for 24 h, and then the medium was 
replaced with 500 µL of Rho-B or Rho-B-2C18 loaded CLPMs solution (0.6 mg/mL) 
(prepared as described before), whose concentration was adjusted by adding DMEM 
containing 4.5 g/L D-Glucose, during 4 hours at 37 ⁰C. Then, CLPMs solution was 
removed and cells were washed 3 times with PBS. Fixation of cells was performed by 
the addition of 300 µL of paraformaldehyde 4% solution and incubation for 20 minutes 
at room temperature. Cells were washed 2 times with PBS. For the co-localization of 
Rho-B labeled CLPMs staining of actin was performed with Alexa Fluor 488 
Phalloidin. Cells were first permeabilized in PBS+1% BSA+ 0.1% saponin and then 
incubated with 40 µL of Alexa Fluor 488 Phalloidin diluted in permeabilization solution 
(1:200) for 1 hour at room temperature in the dark. After washing with PBS-BS 
(PBS+1% BSA + 0.1% saponin), PBS-B (PBS+1% BSA) and distilled water, coverslips 
were mounted and the cell nuclei stained at the same time with 5 µL solution of 
MOWIOL-DAPI (1:1000). After drying, coverslips were sealed with nail polish around 
the edges and stored at 4 ⁰C in the darkness until confocal microscopy observation. 
Cellular uptake and localization was explored by confocal microscopy using a 60x 
objective (Olympus FV10-i Oil Type, Olympus, Spain). Green fluorescence was 
observed under 499/520 (Ex/Em), red fluorescence was observed under 558/575 
(Ex/Em) and DAPI under 359/461 (Ex/Em). Image treatment was done with FV10i-SW 
software (Olympus).  
4.10. Isothermal titration calorimetry (ITC) assay 
24 
Binding of CPT to F127-Ac-8 polymer was determined with a high-sensitivity 
isothermal titration VP-ITC microcalorimeter (MicroCal, USA). Experiments were 
performed at 25°C in aqueous media with 3% of DMSO to increase solubility. 100 µM 
compound solution in the calorimetric cell was titrated with F127-Ac-8 polymer 30 µM 
solution. Control experiments were performed under the same experimental conditions. 
The heat due to the binding reaction was obtained as the difference between the reaction 
heat and the corresponding heat of dilution, the latter estimated as a constant heat 
throughout the experiment, and included as an adjustable parameter in the analysis. Data 
were analyzed using software developed in our laboratory implemented in Origin 7 
(OriginLab, USA). 
4.11. Cells and replicon system 
The highly permissive cell clone Huh 7-Lunet, as well as Huh 7 cells containing 
subgenomic hepatitis C virus (HCV)  replicons I389luc-ubi-neo/NS3-3’/5.1 (Huh 5-2), 
I377NS3-3’/wt (Huh 9-13) or I389/hygro-ubi-NS3-3/5.1 (a kind gift from Dr. V. 
Lohmann and Dr. R. Bartenschlager) have been described recently.[21-24] Briefly, this 
system allowed the efficient propagation of genetically modified HCV RNAs 
(replicons) in a human hepatoma cell line (Huh). The amount of the RNA that has been 
transcribed and translated is determined through the quantification of a reporter 
contained in the replicon system (luciferase). The amount of luminescence detected 
(after adding the substrate specific for this enzyme) is proportional to the virus 
replication rate.[21-24] Cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM; Gibco, Belgium) supplemented with 10% heat-inactivated fetal bovine serum 
(PAN-Biotech GmbH, Germany), 1X non-essential amino acids (Gibco), 100 IU/mL 
penicillin (Gibco), 100 µg/mL streptomycin (Gibco), and 250 µg/mL geneticin (G418; 
Gibco). 
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4.12. Antiviral assay with Huh 5-2 Cells 
Antiviral assays for assessing the efficacy of the F127-Ac-8/CPT CLPMs system were 
performed as described in literature.[21-25] Briefly, Huh 5-2 cells were seeded at a density 
of 5103 cells per well in a tissue culture-treated white 96-well view plate (Techno 
Plastic Products AG, Switzerland) in complete DMEM supplemented with 250 µg/mL 
G418. After incubation for 24 hours at 37°C medium was removed and 2-fold serial 
dilutions in complete DMEM (without G418) of the F127-Ac-8/CPT CLPMs were 
added in a total volume of 100 µL. After 3 days of incubation at 37°C cell culture 
medium was removed and luciferase activity was determined using the Bright-GloTM 
Luciferase Assay System (Promega Corporation, The Netherlands). The luciferase 
signal was measured using a Synergy HT Multimode Reader (BioTek Instruments Inc, 
USA). The 50% effective concentration (EC50) was defined as the concentration of 
compound that reduced the luciferase signal by 50%. 
4.13. Cytostatic assay 
Cytostatic assays for assessing the cell viability of the F127-Ac-8/CPT CLPMs were 
performed as described in literature.[21-24] Briefly, HeLa and Huh 5-2 cell lines were 
seeded at a density of 5103 cells per well of a 96-well plate in complete DMEM (with 
the appropriate concentrations of G418, in case of Huh 5-2). Serial dilutions of the test 
compounds in complete DMEM (without G418) were added 24 hours after seeding. 
Cells were allowed to proliferate for 3 days at 37°C, after which the cell number was 
determined by CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega 
Corporation). The 50% cytostatic concentration (CC50) was determined employing the 
dose-response equation (i.e., Hill equation). All the experiments with HeLa and Huh5-2 
cells were carried out in triplicate and each experiment was repeated three different 
days. 
26 
Supporting Information  
Supporting Information (Chemical characterization details, cell viability studies) is 
available from the Wiley Online Library or from the author. 
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Figure S1. 1H-NMR spectra evolution of generation one Pluronic-bis-MPA dendritic 
derivatives in CDCl3. (a) Pluronic F127 (b) F127-Bn-2 (c) F127-OH-4.  
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Figure S2. 1H-NMR spectra of generation two Pluronic-bis-MPA dendritic derivatives 








Figure S3. Infrared spectra comparison for all Pluronic-bis-MPA dendritic derivatives.  
5 
GPC 
Figure S4. Representative GPC chromatograms of commercial Pluronic F127, synthesis 
intermediates and F127-Ac-8 were carried out using 1 mg/mL solutions in THF and a 
flow speed of 1 mL/min. a), c) and e) carried out with two columns Styragel HR1 and 
HR3 connected in series from Waters; b), d) and f) carried out with two columns PLgel  
MIXED-C and MIXED-E connected in series from Agilent technologies. Dispersities 
are ca. 1.1. Calibration made against polystyrene standards. 
6 
Unspecific cytotoxicity of CLPMs  
The cytotoxicity of CPLMs in HeLa cells was also checked at concentrations higher 
than those used for anti-HCV experiments.  
HeLa cells (Homo sapiens cervix adenocarcinoma, Cancer Research UK, Cell Lines 
Services) were cultured in DMEM containing 4.5 g/L D-Glucose and 4 mM L-
Glutamine. Also, 10% heat-inactivated fetal bovine serum (FBS), 1% 
penicillin/streptomycin and 1% amphotericin B were added to complement the media. 
HeLa cells were maintained at 37⁰C in normoxic conditions (21% O2, 5% CO2).  
HeLa cells were seeded at a density of 5·103 cells per well in 96 well-plates. After 24 
hours of incubation culture medium was removed and F127-Ac-8 CLPMs solutions 
were added. CLPMs were diluted in complete medium /DEMEM) and tested at three 
concentrations: 0.25, 0.5 and 1 mg/mL (ca. 18, 36 and 72 µM, respectively). All 
experiments were carried out in triplicate. The culture medium with CLMPs was 
removed after 24, 48 or 72 hours of incubation and replaced by fresh culture medium 
and 10% of Alamar Blue dye solution. After 3 h incubation at 37 ⁰C, fluorescence was 
read at 530/590 (excitation/emission) on a Synergy HT plate reader (BioTek, USA). 
Untreated cells incubated with medium without CPLMs were used as control. 
Cytotoxicity was expressed as relative viability of cells compared to control cells 
incubated with culture medium only (considered as 100% viability).  
Figure S5. Cell viability for F127-Ac-8 CLMPs with HeLa cells at 0.25, 0.5 and 1 
mg·mL-1. 
